Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q2 FY25 results · Jul–Sep 2024
Natco Pharma reported revenue from operations of ₹1,371.10 crore (up 32.9% from Q2 FY24) and net profit of ₹676.50 crore (up 83.3% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,371.10 | 1,031.40 | +32.9% | 1,362.60 | +0.6% |
| Other income | 63.80 | 29.40 | +117.0% | 48.10 | +32.6% |
| Total income | 1,434.90 | 1,060.80 | +35.3% | 1,410.70 | +1.7% |
| Profit before tax | 818.20 | 439.60 | +86.1% | 803.60 | +1.8% |
| Net profit for the period | 676.50 | 369.00 | +83.3% | 668.50 | +1.2% |
| Attributable to shareholders of the company | 677.30 | 369.00 | +83.6% | 668.50 | +1.3% |
| EPS, basic (₹) | 37.81 | 20.60 | +83.5% | 37.32 | +1.3% |
| Net margin (%) | 49.3 | 35.8 | 49.1 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,292.60 | 930.50 | +38.9% | 1,236.90 | +4.5% |
| Other income | 51.40 | 24.70 | +108.1% | 39.80 | +29.1% |
| Total income | 1,344.00 | 955.20 | +40.7% | 1,276.70 | +5.3% |
| Profit before tax | 796.90 | 424.00 | +87.9% | 758.00 | +5.1% |
| Net profit for the period | 661.10 | 360.20 | +83.5% | 636.30 | +3.9% |
| EPS, basic (₹) | 36.91 | 20.11 | +83.5% | 35.53 | +3.9% |
| Net margin (%) | 51.1 | 38.7 | 51.4 |
Consolidated
- Filed with BSE
- 12 Nov 2024, 15:47 IST
- Board meeting
- 12 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2024, 15:47 IST
- Board meeting
- 12 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE